308 related articles for article (PubMed ID: 21915260)
1. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
Dabora SL; Franz DN; Ashwal S; Sagalowsky A; DiMario FJ; Miles D; Cutler D; Krueger D; Uppot RN; Rabenou R; Camposano S; Paolini J; Fennessy F; Lee N; Woodrum C; Manola J; Garber J; Thiele EA
PLoS One; 2011; 6(9):e23379. PubMed ID: 21915260
[TBL] [Abstract][Full Text] [Related]
2. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.
Sasongko TH; Ismail NF; Nik Abdul Malik NM; Zabidi-Hussin ZA
Orphanet J Rare Dis; 2015 Aug; 10():95. PubMed ID: 26259610
[TBL] [Abstract][Full Text] [Related]
7. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.
Tian X; Glass JE; Kwiatkowski DJ; Towbin AJ; Li Y; Sund KL; Krueger DA; Franz DN; McCormack FX; Gupta N
Ann Am Thorac Soc; 2021 May; 18(5):815-819. PubMed ID: 33171065
[No Abstract] [Full Text] [Related]
8. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
10. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
[TBL] [Abstract][Full Text] [Related]
11. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
12. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Woodrum C; Nobil A; Dabora SL
J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
15. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.
Henske EP; Wessner LL; Golden J; Scheithauer BW; Vortmeyer AO; Zhuang Z; Klein-Szanto AJ; Kwiatkowski DJ; Yeung RS
Am J Pathol; 1997 Dec; 151(6):1639-47. PubMed ID: 9403714
[TBL] [Abstract][Full Text] [Related]
16. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
18. Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas.
Henske EP; Ao X; Short MP; Greenberg R; Neumann HP; Kwiatkowski DJ; Russo I
Mod Pathol; 1998 Jul; 11(7):665-8. PubMed ID: 9688188
[TBL] [Abstract][Full Text] [Related]
19. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]